视神经脊髓炎谱系疾病与MOG抗体相关疾病患者的费用及健康相关生活质量:CHANCENMO研究
这项多中心横断面研究通过患者问卷评估视神经脊髓炎谱系疾病(NMOSD)和髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)的医疗与非医疗资源消耗、工作能力及健康相关生活质量(HRQoL),费用以2018年欧元从社会视角分析。共纳入212例患者,人均年总费用为59574欧元(95%CI 51225-68293),EQ-5D-5L平均指数值为0.693(95%CI 0.65-0.73)。费用与疾病严重程度正相关(ρ=0.56),HRQoL与疾病严重程度负相关(ρ=-0.69);抗体状态和病程均不影响总年费用或HRQoL。
要点
- 人均年总费用59574欧元,主要驱动因素为非正式护理费用(28%)、间接费用(23%)和药物(16%)。
- EDSS 6.5-8.5亚组人均年费用达129687欧元,EQ-5D-5L指数值仅0.195。
- 抗体状态和病程均不影响总年费用或HRQoL。
核心结论
- 这些来自无获批预防性免疫治疗时代的德国数据显示,疾病对费用和生活质量产生巨大影响。
- 应提供早期且具成本效益的治疗,以预防长期残疾并保持生活质量。
研究设计与样本
- 多中心横断面研究,通过患者问卷评估医疗与非医疗资源消耗及工作能力。
- 费用以2018年欧元从社会视角分析,HRQoL采用EQ-5D-5L问卷评估。
- 临床数据取自视神经脊髓炎研究组(NEMOS)数据库。
- 共分析212例患者(80%女性,中位年龄50岁[19-83],中位病程7年[0-43],中位EDSS评分3.5[0-8.5];66%水通道蛋白-4 IgG阳性,22% MOG IgG阳性,12%双抗体阴性)。
主要发现
- EQ-5D-5L平均指数值为0.693(95%CI 0.65-0.73)。
- 最重要的费用驱动因素为非正式护理费用(占总费用28%)、间接费用(23%)和药物(16%),尤其是免疫治疗药物。
- 费用与疾病严重程度正相关(ρ=0.56,95%CI 0.45-0.65);EDSS 6.5-8.5亚组人均年费用为129687欧元(95%CI 101946-160336;合153031美元,95%CI 120296-189196)。
- HRQoL与疾病严重程度负相关(ρ=-0.69,95%CI -0.76至-0.61);EDSS 6.5-8.5亚组EQ-5D-5L平均指数值为0.195(95%CI 0.13-0.28)。
临床怎么用
- 作者认为应提供早期且具成本效益的治疗,以预防长期残疾并保持生活质量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). METHODS: In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. RESULTS: Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease duration 7 [0-43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0-8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225-68,293 or US dollars [USD] 70,297, 95% CI 60,445-80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65-0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ = 0.56, 95% CI 0.45-0.65); in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were €129,687 (95% CI 101,946-160,336 or USD 153,031, 95% CI 120,296-189,196). The HRQoL revealed a negative correlation to disease severity (ρ = -0.69, 95% CI -0.76 to -0.61); in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13-0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. DISCUSSION: These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life.
引用
- Hümmert MW, Schöppe LM, Bellmann-Strobl J, et al. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCENMO Study. Neurology. 2022. PMID: 35082170. doi:10.1212/WNL.0000000000200052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。